Insider Selling: Eli Lilly And Co (NYSE:LLY) SVP Sells $1,086,980.00 in Stock
Eli Lilly And Co (NYSE:LLY) SVP Stephen F. Fry sold 9,452 shares of Eli Lilly And Co stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $115.00, for a total value of $1,086,980.00. Following the sale, the senior vice president now directly owns 100,211 shares of the company’s stock, valued at approximately $11,524,265. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Eli Lilly And Co stock opened at $111.69 on Thursday. The firm has a market cap of $107.23 billion, a price-to-earnings ratio of 20.12, a price-to-earnings-growth ratio of 1.96 and a beta of 0.16. Eli Lilly And Co has a 52 week low of $104.17 and a 52 week high of $132.13. The business’s 50-day moving average price is $111.51 and its 200 day moving average price is $116.94. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 4.98.
Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a return on equity of 70.86% and a net margin of 33.76%. The company had revenue of $5.64 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the previous year, the company posted $1.48 earnings per share. Eli Lilly And Co’s revenue for the quarter was up .9% on a year-over-year basis. Equities analysts expect that Eli Lilly And Co will post 5.72 EPS for the current year.
LLY has been the topic of a number of research reports. Bank of America set a $120.00 price objective on Eli Lilly And Co and gave the company a “neutral” rating in a report on Tuesday. ValuEngine downgraded Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Goldman Sachs Group started coverage on Eli Lilly And Co in a research report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, May 21st. Nine analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Eli Lilly And Co has an average rating of “Buy” and an average price target of $122.93.
Several large investors have recently bought and sold shares of LLY. Nuveen Asset Management LLC lifted its stake in shares of Eli Lilly And Co by 20,030.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock valued at $804,983,000 after purchasing an additional 7,229,751 shares during the period. Renaissance Technologies LLC grew its position in Eli Lilly And Co by 218.6% during the second quarter. Renaissance Technologies LLC now owns 2,308,601 shares of the company’s stock valued at $255,770,000 after buying an additional 1,583,947 shares during the period. Grantham Mayo Van Otterloo & Co. LLC grew its position in Eli Lilly And Co by 5,612.3% during the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,591,396 shares of the company’s stock valued at $176,311,000 after buying an additional 1,563,537 shares during the period. AQR Capital Management LLC increased its holdings in Eli Lilly And Co by 53.3% in the second quarter. AQR Capital Management LLC now owns 4,335,702 shares of the company’s stock valued at $480,048,000 after buying an additional 1,507,050 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in Eli Lilly And Co by 1.5% in the second quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock valued at $6,866,670,000 after buying an additional 898,845 shares in the last quarter. 76.78% of the stock is owned by hedge funds and other institutional investors.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Story: What is a Backdoor Roth IRA?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.